GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Orexo AB (OSTO:ORX) » Definitions » EV-to-EBIT

Orexo AB (OSTO:ORX) EV-to-EBIT

: -8.75 (As of Today)
View and export this data going back to 2005. Start your Free Trial

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Orexo AB's Enterprise Value is kr867.1 Mil. Orexo AB's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was kr-99.1 Mil. Therefore, Orexo AB's EV-to-EBIT for today is -8.75.

The historical rank and industry rank for Orexo AB's EV-to-EBIT or its related term are showing as below:

OSTO:ORX' s EV-to-EBIT Range Over the Past 10 Years
Min: -194.22   Med: -5.81   Max: 29.28
Current: -8.75

During the past 13 years, the highest EV-to-EBIT of Orexo AB was 29.28. The lowest was -194.22. And the median was -5.81.

OSTO:ORX's EV-to-EBIT is ranked worse than
100% of 669 companies
in the Drug Manufacturers industry
Industry Median: 17.06 vs OSTO:ORX: -8.75

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Orexo AB's Enterprise Value for the quarter that ended in Dec. 2023 was kr835.4 Mil. Orexo AB's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was kr-99.1 Mil. Orexo AB's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -11.86%.


Orexo AB EV-to-EBIT Historical Data

The historical data trend for Orexo AB's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Orexo AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBIT
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.90 -67.89 -6.33 -5.86 -8.43

Orexo AB Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-EBIT Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -5.86 -4.12 -4.11 -6.52 -8.43

Competitive Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Orexo AB's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Orexo AB EV-to-EBIT Distribution

For the Drug Manufacturers industry and Healthcare sector, Orexo AB's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Orexo AB's EV-to-EBIT falls into.



Orexo AB EV-to-EBIT Calculation

Orexo AB's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=867.084/-99.1
=-8.75

Orexo AB's current Enterprise Value is kr867.1 Mil.
Orexo AB's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-99.1 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Orexo AB  (OSTO:ORX) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Orexo AB's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Dec. 2023 ) =EBIT / Enterprise Value (Q: Dec. 2023 )
=-99.1/835.390816
=-11.86 %

Orexo AB's Enterprise Value for the quarter that ended in Dec. 2023 was kr835.4 Mil.
Orexo AB's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-99.1 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Orexo AB EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Orexo AB's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Orexo AB (OSTO:ORX) Business Description

Traded in Other Exchanges
Address
Virdings alle 32 A, P.O. Box 303, Uppsala, SWE, 75105
Orexo AB has operations in Sweden and the United States. Operations are monitored and presented in the segments US Pharma, Digital Therapeutics (DTx) and HQ & Pipeline. The majority is from the US Pharma segment. Geographically, the majority is derived from the United States. US Pharma includes the commercialization of fully owned pharmaceuticals in the United States market. Digital Therapeutics include the commercialization of Orexo's groundbreaking evidence-based digital therapeutics, mainly in the United States market, which is in an early development stage. HQ &Pipeline include the Development of pharmaceuticals performed at Orexo's headquarters in Uppsala, Sweden.

Orexo AB (OSTO:ORX) Headlines

No Headlines